Rochester, NY 7/31/2009 4:34:48 PM
After Hours - Hemispherx Biopharma, Inc. HEB, Hemispherx: Decision of the FDA on Ampligen won’t come until fall
Hemispherx Biopharma, Inc.
FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because the company is experiencing a staffing problems, said Dr. William Carter, the company's president and CEO. While the agency reviews the product, the biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners.
http://WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Scroll to the bottom of this page to sign up for our FREE stock alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither WhisperFromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers.
